A photo that shows the Swiss pharmaceutical giant logo in Basel.
Sebastien Bozon | AFP | Getty images
Swiss pharmaceutical giant Roche On Tuesday, he said he would invest $ 50 billion in the US.
The investment will create more than 12,000 jobs, Roche said: 1,000 with the company and the rest to support the new manufacturing capabilities of the United States. The firm said it already uses more than 25,000 people in the United States.
Roche’s shares were 1.1% lower at 8:39 am in London.
The pharmaceutical giant will inject effective in the creation of new generation research and development sites (R&D), while reinforcing and expanding manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California. A new R&D site in Massachusetts will be used for AI investigation and will act as a center for the research of cardiovascular, renal and metabolism treatments.
The financing package will also be used to build a new 900,000 square feet manufacturing center in an unknown location to support the “portfolio expansion of the next -generation weight” medications.
Once the new manufacturing capacity investments are completed, Roche said that more US medications would export. UU. Than imports.
Pharmaceutical companies have been fighting to reinforce their presence from the United States amid threats from President Donald Trump to end the exemption of the import rate industry.
“We are going to announce very soon an important rate about pharmaceutical products,” he said earlier this month.
Roche’s investment follows similar movements of the main rivals. Earlier this month, Novartis of Switzerland announced plans to invest $ 23 billion in the construction and expansion of 10 US facilities, in a movement that, he said, creates more than 4,000 jobs.
The British pharmaceutical giant Astrazeneca Last Moth said he would invest $ 2.5 billion in the creation of a Beijing center. However, the company’s CEO, Pascal Soriiot, told CNBC at that time that Astrazeneca was still “very committed to the United States”, where he has two “very large” research and development centers.
The CEO of Roche, Thomas Schinecker, said in a statement on Tuesday that the new investment of $ 50 million of the company demonstrated its “long -standing commitment to research, development and manufacturing in the United States.”
“We are proud of our 110 -year legacy in the United States, which has been a key driver for jobs, innovation and the creation of intellectual property in the United States, Acrosh both our pharmaceutical and diagnostic divisions,” he said. “Our USD 50 billion investments in the next five years will lay the foundations for our next era of innovation and growth, they will benefit patients in the United States and worldwide.”